POEM - Patient Orientated Eczema Measure

Technology No.

The Patient Oriented Eczema Measure (POEM) is a simple, validated self-report questionnaire used for monitoring atopic eczema severity. It records seven symptoms shown to be important to patients. It is widely used in paper and electronic form for assessing and tracking eczema activity, both in clinical trials and in normal clinical practice. POEM is recommended by the National Institute for Health and Care Excellence (NICE) for assessing the severity of atopic dermatitis in NHS practice and has been recommended by the international Harmonising Outcome Measures for Eczema (HOME) group as a core outcome measure for eczema trials and for routine clinical practice. 

About using POEM

1. Further information about how POEM was developed, translations available and best practice for its use is available from the Centre for Evidence Based Dermatology

2. POEM is free to use for non-commercial use, including public healthcare (government-funded), non-commercial research and personal use (please visit https://www.nottingham.ac.uk/research/groups/cebd/resources/poem.aspx). You do not need a license to use POEM for research use or to create a translation. If you are using the POEM instrument for non-commercial uses (e.g academic studies or in your clinic, we request that you send us an email with details of how you plan to use the scale (cebd@nottingham.ac.uk). This helps us track impact.

3. Since September 2022, POEM for commercial use (e.g commercial clinical trials) has required a fee. It is downloadable for commercial use exclusively via this website. If you have a query regarding the nature of your usage, then please get in touch. Commercial use of POEM implies that you agree to the Terms and Conditions that will download alongside POEM through this website.

4. POEM is copyright of the University of Nottingham.

5. Poem is available commercially on a per patient basis i.e if a clinical trial has 50 enrolled patients, 50 'users' must be purchased, regardless of the number of data collection time points for each participant. When selecting the number of 'users' on the payment page, make this equal to the number of enrolled patients. If more patients enrol after initial purchase, please return and purchase the additional number of patients. 

6. For any scale related queries please contact cebd@nottingham.ac.uk, for queries regarding payment or licencing please contact iain.bower@nottingham.ac.uk

  • swap_vertical_circlelibrary_booksReferences (8)
    1. Charman C, Venn A, Williams HC. (2004), The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective., Arch Dermatol, 140, 1513-1519
    2. Charman CR, Venn AJ, Ravenscroft JC, Williams HC. (2013), Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods., Br J Dermatol., 169(6), 1326–1332
    3. Spuls PI, Gerbens LA, Simpson E, Apfelbacher CJ, Chalmers JR, Thomas KS, Prinsen CA, von Kobyletzki LB, Singh JA, Williams HC, Schmitt J, HOME initiative collaborators (2016), POEM a core instrument to measure symptoms in clinical trials: a HOME statement., Br J Dermatol
    4. E. Grinich, J. Schmitt, D. Küster, P.I. Spuls, H.C. Williams, J.R. Chalmers, K.S. Thomas, C. Apfelbacher, C.A.C. Prinsen, M. Furue, B. Stuart, B. Carter and E. Simpson. (2018), Standardized Reporting of the Eczema Area and Severity Index (EASI) and the Patient-Oriented Eczema Measure (POEM): A Recommendation by the Harmonising Outcome Measures for Eczema (HOME) Initiative., Br J Dermatol
    5. Schram ME, Spuls PI, Leeflang MM, Lindeboom R, Bos JD, Schmitt (2016), The Patient-Oriented Eczema Measure in young children: responsiveness and minimal clinically important difference., Allergy
    6. Schram ME, Spuls PI, Leeflang MM, Lindeboom R, Bos JD, Schmitt J (2012), EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference., Allergy, 67(1), 99-106
    7. Howells L, Ratib S, Chalmers JR, Bradshaw L, Thomas KS; CLOTHES trial team (2018), How should minimally important change (MIC) scores for the Patient Oriented Eczema Measure (POEM) be interpreted? A validation using varied methods., Br J Dermatol.
    8. L. Howells, S. Gran, J. R. Chalmers, B. Stuart, M. Santer, L. Bradshaw, D. M. Gaunt, M. J. Ridd, L. A. A. Gerbens, P. I. Spuls, C. Huang, N. A. Francis, K. S. Thomas. (2021), Do patient characteristics matter when calculating sample size for eczema clinical trials? L., Skin Health and Dis., e42
  • swap_vertical_circlecloud_downloadSupporting documents (0)
    Additional files may be available once you've completed the transaction for this product. If you've already done so, please log into your account and visit My account / Downloads section to view them.
POEM licence

Term: perpetual

Price per user:
£14.00 excl. VAT